Amgen Inc (BUE:AMGN)
ARS 10400 250 (2.46%) Market Cap: 151.64 Til Enterprise Value: 203.40 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 57/100

Amgen Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 01:10PM GMT
Release Date Price: ARS2477
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Matthew Harrison, one of the biotech analysts here.

Before we get started, I just need to read the disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up your very own copy at the registration desk. So very pleased to have Amgen for our next session. Bob Bradley, who's the CEO; and David Meline, the CFO, up here on stage. Bob, I know you want to probably make some opening comments, and then we can jump into it.

Robert A. Bradway
Amgen Inc. - Chairman, CEO & President

Thank you, Matthew. Well, let me start by thanking you and your colleagues for hosting this event. Appreciate you having us here and appreciate all of you being with us in the room this morning.

I think as you saw, Matthew, through the report of the first 2 quarters, we're executing well into 2019. For us,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot